OncoSynergy announced that it has submitted an FDA application for a first-in-human trial of its Orphan Drug designated experimental therapeutic OS2966 for malignant brain cancer. Read press release > click here Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window)Like this:Like Loading... Related